Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2006-10-03
2006-10-03
Yaen, Christopher (Department: 1643)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C530S387100
Reexamination Certificate
active
07115722
ABSTRACT:
The present invention relates to monoclonal antibody H11 and antigen binding fragments that specifically bind to the antigen recognized by H11, the C-antigen. The C-antigen is found specifically on neoplastic cells and not on normal cells. Also disclosed are polynucleotide and polypeptide derivatives based on H11, including single chain V region molecules and fusion proteins, and various pharmaceutical compositions. When administered to an individual, the H11 antibody is effective in diagnosing, localizing, and/or treating neoplasias. The invention further provides methods for treating a neoplastic disease, particularly melanoma, neuroblastoma, glioma, soft tissue sarcoma, and small cell lung carcinoma. Patients who are in remission as a result of traditional modes of cancer therapy may be treated with a composition of this invention in hopes of reducing the risk of recurrence. Patients may also be treated concurrently with the antibodies and traditional anti-neoplastic agents.
REFERENCES:
patent: 3817837 (1974-06-01), Rubenstein et al.
patent: 3850752 (1974-11-01), Schuur et al.
patent: 3939350 (1976-02-01), Kronick et al.
patent: 3996345 (1976-12-01), Ullman et al.
patent: 4275149 (1981-06-01), Litman et al.
patent: 4277437 (1981-07-01), Maggio
patent: 4366241 (1982-12-01), Tom et al.
patent: 4618477 (1986-10-01), Babu et al.
patent: 4683195 (1987-07-01), Mullis et al.
patent: 4683202 (1987-07-01), Mullis
patent: 4754065 (1988-06-01), Levenson et al.
patent: 4800159 (1989-01-01), Mullis et al.
patent: 4983586 (1991-01-01), Bodor
patent: 5002935 (1991-03-01), Bodor
patent: 5017566 (1991-05-01), Bodor
patent: 5153179 (1992-10-01), Eibl
patent: 5270202 (1993-12-01), Raychaudhuri
patent: 5474755 (1995-12-01), Hanna, Jr. et al.
patent: 5530101 (1996-06-01), Queen et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 0 329 400 (1989-08-01), None
patent: 0 699 755 (1996-03-01), None
patent: WO 91/04014 (1991-04-01), None
patent: WO 92/20799 (1992-11-01), None
patent: WO 93/07286 (1993-04-01), None
patent: WO 95/35374 (1995-12-01), None
Reiger et al (Glossary of Genetics and Cytogenetics, Classical and Molecular, 4th Ed., Springer-Verlay, Berlin, 1976).
Westwood et al (Epitope Mapping 2001;chapter 1 pp. 5-6).
(Weiner L.M., Seminars Oncology, vol. 26, No. 4, Suppl 12, pp. 41-50, 1999).
Gura (Science, v278, 1997, pp. 1041-1042).
Marchant, “Contemporary management of breast cancer”Obstetrics and Gynecology Clinics of North America(1994) 21:555-560.
Colditz, “Epidemiology of breast cancer”Cancer(1993) 71:1480-1489.
Kohn et al., “Molecular insights into cancer invasion: Strategies for prevention and intervention”Cancer Res.(1995) 55:1856-1862.
Koda et al., “Three step radioimmunodiagnosis of colon cancers using murine and human monoclonal antibodies”Am. J. Gastroenterol.(1995) 90: Abstract No. 357.
Hall, “Monoclonal antibodies at age 20: Promise at last?”Science(1995) 270:915-916.
Schattner, “The origin of autoantibodies”Immunol. Lett.(1986/1987) 14:143-153.
Lutz et al., “Naturally occurring autoantibodies to skeletal proteins from human red blood cells”J. Immunol.(1982) 128:1695-1699.
Guilbert et al., “Naturally occurring antibodies against nine common antigens in human sera” J. Immunol. (1982) 128:2779-2787.
Glassy, “Immortalization of human lymphocytes from a tumor-involved lymph node”Cancer Res.(1987) 47:5181-5188.
Fischer et al., “Paucity of humoral response in patients to glioma-associated antigen(s): Antigen localization by immunofluorescence”Immunobiol. of Proteins and Peptides VI(1991) M. Atassi, ed., Plenum Press, NY, pp. 263-270.
Skerra, “Bacterial expression of immunoglobulin fragments”Curr. Opin. Immunol..(1993) 5:256-262.
Fiedler et al., “High-level production and long-term storage of engineered antibodies in transgenic tobacco seeds”Bio/Technology(1995) 13:1090-1093.
Zhang et al., “A human monoclonal antimelanoma single-chain Fv antibody derived from tumor-infiltrating lymphocytes”Cancer Res.(1995) 55:3584-3591.
Barbas, “Synthetic human antibodies”Nature Med.(1995) 1:837-839.
Yoshikawa et al., “A human monoclonal antibody recognizing a surface antigen on stomach cancer cells” Jpn. J. Cancer Res. (1989) 80:546-553.
Yamaguchi et al., “Cell-surface antigens of melanoma recognized by human monoclonal antibodies”Proc. Natl. Acad. Sci. USA(1987) 84:2416-2420.
Haspel et al., “Generation of tumor cell-reactive human monoclonal antibodies using peripheral blood lymphocytes from actively immunized colorectal carcinoma patients”Cancer Res.(1985) 45:3951-3961.
Cote et al., “Specificity analysis of human monoclonal antibodies reactive with cell surface and intracellular antigens”Proc. Natl. Acad. Sci. USA(1986) 83:2959-2963.
Glassy, “Immortalization of human lymphocytes from a tumor-involved lymph node”Cancer Res.(1987) 47:5181-5188.
Borup-Christensen et al., “Human-human hybridomas generated with lymphocytes from patients with colorectal cancer”Cancer Detect. Prevent. Suppl.(1987) 1:207-215.
Kan-Mitchell et al., “Tumor-reactive human immunoglobulin G monoclonal antibody from a melanoma patient”Cancer Res.(1989) 49:4536-4541.
Yoshikawa et al., “Human monoclonal antibody reactive to stomach cancer produced by mouse-human hybridoma technique”Jpn. J. Cancer Res.(1986) 77:1122-1133.
Olsson, “Human monoclonal antibodies in experimental cancer research”J. Nat. Cancer Inst.(1985) 75:397-403.
Larrick et al., “Prospects for the therapeutic use of human monoclonal antibodies”J. Biol. Response Mod.(1986) 5:379-393.
McCabe et al., “Preclinical studies on the pharmacokinetic properties of human monoclonal antibodies to colorectal cancer and their use for detection of tumors”Cancer Res.(1988) 48:4348-4353.
Cohen, “Cancer vaccines get a shot in the arm”Science(1993) 262:841-843.
Ditzel et al., “Immunoscintigraphy of colon cancers with the human monoclonal antibody COU-1”Cancer(1994) 73:858-863.
Alonso, “Human-human monoclonal antibody directed against tumor surface antigen in the treatment of human malignancy”Am. J. Clin. Oncol.(1991) 14:463-471.
Mack et al., “A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity”Proc. Natl. Acad. Sci. USA(1995) 92:7021-7025.
Cheresh et al., “Disialoganglioside GD3 on human melanoma serves as a relevant target antigen for monoclonal antibody-mediated tumor cytolysis”Proc. Natl. Acad. Sci USA(1985) 82:5155-5159.
Cheresh et al., “Biosynthesis and expression of the disialoganglioside GD2,a relevant target antigent on small cell lung carcinoma for monoclonal antibody-mediated cytolysis”Cancer Res.(1986) 46:5112-5118.
Murakami et al., “Human-human hybridomas secreting antibodies specific to human lung carcinoma”In Vitro Cell.&Dev. Biol.(1985) 21:593-596.
Schadendorf et al., “A novel heteromorphic human cell surface alloantigen, gp60, defined by a human monoclonal antibody”J. Immunol.(1989) 142:1621-1625.
Pickering et al., “Human monoclonal antibodies to cytokeratins associated with squamous cell carcinoma”Clin. Immunol. Immunopathol.(1984) 32:253-260.
Hagiwara et al., “Human x human hybridoma producing monoclonal antibody against autologous cervical carcinoma”Mol. Biol. Med.(1983) 1:245-252.
Schlom et al., “Generation of human monoclonal antibodies reactive with human mammary carcinoma cells”Proc. Natl. Acad. Sci.USA (1980) 77:6841-6845.
Finn et al., “MUC-1 epithelial tumor mucin-based immunity and cancer vaccines”Immunol. Rev.(1995) 145:61-89.
Matsumoto et al., “Clinical phase I study of human monoclonal antibody, ACA 11 (CLN-IgG) against human malignant brain tumors”The Cli
Dan Michael D.
Kaplan Howard A.
Maiti Pradip K.
Morrison & Foerster / LLP
Viventia Biotech Inc.
Yaen Christopher
LandOfFree
Antigen binding fragments that specifically detect cancer... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antigen binding fragments that specifically detect cancer..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antigen binding fragments that specifically detect cancer... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3655088